FDA Oncology Announcements

Anti-DLL3-CD3 bispecific × Clear all

2 Announcements

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

Trial: DeLLphi-304
Drug: Imdelltra (tarlatamab-dlle) · Anti-DLL3-CD3 bispecific antibody
Condition: Thoracic

FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer

Trial: DeLLphi-301
Drug: Imdelltra (tarlatamab-dlle) · Anti-DLL3-CD3 bispecific antibody
Condition: Thoracic